Aliases:This biomarker is also known as:
- diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein),
- Cholecystokinin-Releasing Peptide, Trypsin-Sensitive,
- Acyl-CoA-Binding Protein,
- Diazepam-Binding Inhibitor,
- Acyl-Coenzyme A Binding Domain Containing 1,
- GABA Receptor Modulator,
DBI, diazepam binding inhibitor, was previously known as ACBP, acyl-coA binding protein. This protein is regulated by hormones, is involved in lipid metabolism, and is thought to act as a neuropeptide to regulate the action of the GABA receptor. DBI is conserved across species. The most highly conserved domain is the hydrophobic binding site for medium- and long-chain acyl-coA esters. DBI is involved in the regulation of pancreatic secretion and release of cholecystokinin. There are three pseudogenes for DBI on separate chromosomes. DBI has multiple transcript variants encoding different isoforms.
|QA State:||Under Review|
There are no datasets associated with this biomarker.